CN Patent

CN107530361A — 用于调节骨密度的方法

Assigned to Ntercept Pharmaceuticals Inc · Expires 2018-01-02 · 8y expired

What this patent protects

本发明涉及在需要治疗的受试者中治疗与骨密度变化相关联的疾病或病状、骨质疏松症或骨质减少疾病、降低这些疾病或病状的风险、预防这些疾病或病状或缓解这些疾病或病状的症状，或者诱导骨发生或骨生长，或者减缓、预防或逆转骨密度降低的方法，这些方法包括向该受试者给予本发明的化合物。

USPTO Abstract

本发明涉及在需要治疗的受试者中治疗与骨密度变化相关联的疾病或病状、骨质疏松症或骨质减少疾病、降低这些疾病或病状的风险、预防这些疾病或病状或缓解这些疾病或病状的症状，或者诱导骨发生或骨生长，或者减缓、预防或逆转骨密度降低的方法，这些方法包括向该受试者给予本发明的化合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN107530361A
Jurisdiction
CN
Classification
—
Expires
2018-01-02
Drug substance claim
No
Drug product claim
No
Assignee
Ntercept Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.